Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPLQ1V)

Drug Name
IFX-1 Drug Info
Synonyms IFX-1 mab
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [1]
Hidradenitis suppurativa ED92.0 Phase 2 [2]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
137254326
TTD Drug ID
DMPLQ1V

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN complement C5 alpha (C5A) TTRJ91Q CO5_HUMAN (678-1676) Inhibitor [3]
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04333420) Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology